Cited by 219Nanoparticle-Based Drug DeliveryAlzheimer's disease research and treatmentsAdvanced Drug Delivery Systems

The DOI matches its Crossref record; 351 of the 352 references it cites were found in a registry or an index.

Neurotherapeutic applications of nanoparticles in Alzheimer’s disease

Sahni, Jasjeet Kaur, Doggui, Sihem, Ali, Javed, Baboota, Sanjula, Dao, Lé, Ramassamy, Charles·2011·Journal of Controlled Release

DOI 10.1016/j.jconrel.2010.11.033

Open this paper in CoChat — free account

Abstract

A rapid increase in incidence of neurodegenerative disorders has been observed with the aging of the population. Alzheimer's disease (AD) is the most common neurodegenerative disorder among the elderly. It is characterized by memory dysfunction, loss of lexical access, spatial and temporal disorientation and impairment of judgement clinically. Unfortunately, clinical development of drugs for the symptomatic and disease-modifying treatment of AD has resulted in both promise and disappointment. Indeed, a large number of drugs with differing targets and mechanisms of action were investigated with only a few of them being clinically available. The targeted drug delivery to the central nervous system (CNS), for the diagnosis and treatment of neurodegenerative disorders such as AD, is restricted due to the limitations posed by the blood-brain barrier (BBB) as well as due to opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Over the last decade, nanoparticle-mediated drug delivery represents one promising strategy to successfully increase the CNS penetration of several therapeutic moieties. Different nanocarriers are being investigated to treat and diagnose AD by delivering at a constant rate a host of therapeutics over times extending up to days, weeks or even months. This review provides a concise incursion on the current pharmacotherapies for AD besides reviewing and discussing the literature on the different drug molecules that have been successfully encapsulated in nanoparticles (NPs). Some of them have been shown to cross the BBB and have been tested either for diagnosis or treatment of AD. Finally, the route of NPs administration and the future prospects will be discussed.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2010.11.033

Cites

351 of 351 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: α-Lipoic acid exhibits anti-amyloidogenicity for β-amyloid fibrils in vitro
Ono, K., Hirohata, M., & Yamada, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.063 · Cited by 60
Retracted
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Structure-antioxidant activity relationships of flavonoids and phenolic acids
Rice-Evans, C. A., Miller, N. J., & Paganga, G. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02227-9 · Cited by 9,085
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Dietary Intake and Bioavailability of Polyphenols
Scalbert, A., & Williamson, G. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.8.2073s · Cited by 3,658
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627

Show all 352 references

Research works printed but not linked: 7

Singh, 2008, Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms, J. Agric. Food Chem., 56, 4855, 10.1021/jf0735073 · DOI
Bieschke, 2010, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl Acad. Sci. USA, 107, 7710, 10.1073/pnas.0910723107 · DOI
Jang, 2003, Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death, Free Radic. Biol. Med., 34, 1100, 10.1016/S0891-5849(03)00062-5 · DOI
Sharma, 2002, Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats, Life Sci., 71, 2489, 10.1016/S0024-3205(02)02083-0 · DOI
Wilson, 2010, Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine, Nanomed. Nanotechnol. Biol. Med., 6, 144, 10.1016/j.nano.2009.04.001 · DOI
Wilson, 2008, Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease, Brain Res., 1200, 159, 10.1016/j.brainres.2008.01.039 · DOI · Paper page
Reiter, 2003, Melatonin: clinical relevance, Best Pract. Res. Clin. Endocrinol. Metab., 17, 273, 10.1016/S1521-690X(03)00016-2 · DOI

Sorted by citations

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 544
Bioavailability enhancers of herbal origin: An overview
Kesarwani, K., & Gupta, R. (2013) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(13)60060-x · Cited by 499
Nanoparticles in Drug Delivery: From History to Therapeutic Applications
Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379
Nanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers
Poovaiah, N., Davoudi, Z., Peng, H., Schlichtmann, B. W., Mallapragada, S. K., Narasimhan, B., & Wang, Q. (2018) · Nanoscale · doi:10.1039/c8nr04073g · Cited by 231
PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood–brain barrier
Fornaguera, C., Dols-Pérez, A., Calderó, G., García, M. J. N., Camarasa, J., & Solans, C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.002 · Cited by 221
Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression
Haque, S., Md, S., Sahni, J. K., Ali, J., & Baboota, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.10.011 · Cited by 219
Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier
Krol, S., Macrez, R., Docagne, F., Defer, G. L., Laurent, S., Rahman, M., Hajipour, M. J., Kehoe, P. G., & Mahmoudi, M. (2012) · Chemical Reviews · doi:10.1021/cr200472g · Cited by 219
A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease
Huo, X., Zhang, Y., Jin, X., Li, Y., & Zhang, L. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.11.008 · Cited by 213
Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery
Nasr, M. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1092619 · Cited by 208
Pharmaceutical nanotechnology: from the bench to the market
Mazayen, Z. M., Ghoneim, A. M., Elbatanony, R. S., Basalious, E. B., & Bendas, E. R. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00400-0 · Cited by 208
Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease
Sun, D., Li, N., Zhang, W., Zhao, Z., Mou, Z., Huang, D., Liu, J., & Wang, W. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.08.052 · Cited by 202
Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles
Jelvehgari, M., Salatin, S., Barar, J., Barzegar-Jalali, M., Adibkia, K., & Kiafar, F. (2017) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.199041 · Cited by 188
Recent advances in nanoparticle-mediated drug delivery
Kumar, B. D., Jalodia, K., Kumar, P., & Gautam, H. K. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.07.019 · Cited by 189
Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 178
Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer’s disease: pharmaceutical, biological, and toxicological studies
Elnaggar, Y. S. R., Etman, S. M., Abdelmonsif, D. A., & Abdallah, O. Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87336 · Cited by 171
Design of LVFFARK and LVFFARK-Functionalized Nanoparticles for Inhibiting Amyloid β-Protein Fibrillation and Cytotoxicity
Xiong, N., Dong, X., Zheng, J., Liu, F., & Sun, Y. P. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00915 · Cited by 160
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Neuronal Uptake and Neuroprotective Effect of Curcumin-Loaded PLGA Nanoparticles on the Human SK-N-SH Cell Line
Doggui, S., Sahni, J. K., Arseneault, M., Dao, L. H., & Ramassamy, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112141 · Cited by 152
Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours
Garg, J., Pathania, K., Sah, S. P., & Pawar, S. V. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00414-8 · Cited by 149
Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery
Sarvaiya, J., & Agrawal, Y. K. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.08.052 · Cited by 140
Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders
Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140
Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities
Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00284 · Cited by 140
Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer's type
Muller, A. P., Ferreira, G. K., Pires, A. J., Silveira, G. D. B., de Souza, D. L., Brandolfi, J. D. A., de Souza, C. T., Paula, M. M. D. S., & Silveira, P. C. L. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.283 · Cited by 132
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129
Polyphenols Beyond Barriers: A Glimpse into the Brain
Figueira, I., Menezes, R., Macedo, D., Costa, I., & dos Santos, C. N. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666161026151545 · Cited by 134
Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E
Neves, A. R., Queiroz, J. F., Weksler, B., Romero, I. A., Couraud, P.-O., & Reis, S. (2015) · Nanotechnology · doi:10.1088/0957-4484/26/49/495103 · Cited by 122
Curcumin- and Fish Oil-Loaded Spongosome and Cubosome Nanoparticles with Neuroprotective Potential against H2O2-Induced Oxidative Stress in Differentiated Human SH-SY5Y Cells
Rakotoarisoa, M., Angelov, B., Garamus, V. M., & Angelova, A. (2019) · ACS Omega · doi:10.1021/acsomega.8b03101 · Cited by 125
The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease
Jayasena, T., Poljak, A., Smythe, G. A., Braidy, N., Münch, G. W., & Sachdev, P. S. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.06.003 · Cited by 122
Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review
Kulkarni, A. D., Vanjari, Y. H., Sancheti, K. H., Belgamwar, V. S., Surana, S. J., & Pardeshi, C. V. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1020809 · Cited by 117
Loading into Nanoparticles Improves Quercetin's Efficacy in Preventing Neuroinflammation Induced by Oxysterols
Testa, G., Gamba, P., Badıllı, U., Gargiulo, S., Maina, M., Guina, T., Calfapietra, S., Biasi, F., Cavalli, R., Poli, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096795 · Cited by 114
Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases
Fornaguera, C., Feiner‐Gracia, N., Calderó, G., García, M. J. N., & Solans, C. (2015) · Nanoscale · doi:10.1039/c5nr03474d · Cited by 108
Engineered Polymer Nanoparticles Containing Hydrophobic Dipeptide for Inhibition of Amyloid-β Fibrillation
Skaat, H., Chen, R., Grinberg, I., & Margel, S. (2012) · Biomacromolecules · doi:10.1021/bm3011177 · Cited by 104
SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in AβPP/PS-1 Transgenic Mouse Brain
Sillerud, L. O., Solberg, N. O., Chamberlain, R., Orlando, R. A., Heidrich, J. E., Brown, D. C., Brady, C. I., Jagt, T. A. V., Garwood, M., & Jagt, D. L. V. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121171 · Cited by 106
Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management
Siddiqi, K. S., Husen, A., Sohrab, S. S., & Yassin, M. O. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2638-7 · Cited by 104
Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S., Chougule, M. B., Shoyele, S., Gupta, U. D., Ajazuddin, M., et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
Nanomedicine for the Treatment of Alzheimer’s Disease
Gregori, M., Masserini, M., & Mancini, S. (2015) · Nanomedicine · doi:10.2217/nnm.14.206 · Cited by 100
The influence of nanoparticulate drug delivery systems in drug therapy
Aminu, N., Bello, I., Umar, N. M., Tanko, N., Aminu, A., & Audu, M. M. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101961 · Cited by 102
Intranasal therapeutic strategies for management of Alzheimer’s disease
Sood, S., Jain, K., & Gowthamarajan, K. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2013.876644 · Cited by 99
Nanotechnology for Alzheimer’s disease detection and treatment
Nazem, A., & Mansoori, G. A. (2011) · Insciences Journal · doi:10.5640/insc.0104169 · Cited by 96
Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease
Ismail, M. F., ElMeshad, A. N., & Salem, N. A. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s39232 · Cited by 95
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer’s disease models
Bernardi, A., Frozza, R. L., Meneghetti, Hoppe, Battastini, A. M. O., Pohlmann, Guterres, S. S., & Salbego (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s35333 · Cited by 91
Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance
Yao, L., Gu, X. Q., Song, Q., Wang, X., Huang, M., Meng, H., Hou, L., Kang, T., Chen, J., Chen, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.055 · Cited by 91
Transferrin-functionalized lipid nanoparticles for curcumin brain delivery
Neves, A. R., van der Putten, L., Queiroz, J. F., Pinheiro, M., & Reis, S. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.03.010 · Cited by 92
Levodopa-loaded nanoparticles for the treatment of Parkinson's disease
van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 85
Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders
Rakotoarisoa, M., & Angelova, A. (2018) · Medicines · doi:10.3390/medicines5040126 · Cited by 85
Role of curcumin and its nanoformulations in neurotherapeutics: A comprehensive review
Mandal, M., Jaiswal, P., & Mishra, A. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22478 · Cited by 89
Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer’s disease
Faustino, C. M. C., Rijo, P. M., & Reis, C. P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.020 · Cited by 82
In Vitro Modulation of TrkB Receptor Signaling upon Sequential Delivery of Curcumin-DHA Loaded Carriers Towards Promoting Neuronal Survival
Guerzoni, L. P. B., Nicolas, V., & Angelova, A. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2080-4 · Cited by 81
Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases
Fakhri, S., Abdian, S., Zarneshan, S. N., Moradi, S. Z., Farzaei, M. H., & Abdollahi, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s347187 · Cited by 83
Nanoparticle-mediated approaches for Alzheimer’s disease pathogenesis, diagnosis, and therapeutics
Hettiarachchi, S. D., Zhou, Y., Seven, E. S., Lakshmana, M. K., Kaushik, A. K., Chand, H. S., & Leblanc, R. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.034 · Cited by 77
Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
Jokar, S., Khazaei, S., Behnammanesh, H., Shamloo, A., Erfani, M., Beiki, D., & Bavi, O. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00606-2 · Cited by 76
Enhanced Brain Delivery of Deferasirox–Lactoferrin Conjugates for Iron Chelation Therapy in Neurodegenerative Disorders: In Vitro and in Vivo Studies
Kamalinia, G., Khodagholi, F., Atyabi, F., Amini, M., Shaerzadeh, F., Sharifzadeh, M. S., & Dinarvand, R. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4002014 · Cited by 73
Oral Brain-Targeted Microemulsion for Enhanced Piperine Delivery in Alzheimer’s Disease Therapy: In Vitro Appraisal, In Vivo Activity, and Nanotoxicity
Etman, S. M., Elnaggar, Y. S. R., Abdelmonsif, D. A., & Abdallah, O. Y. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1180-3 · Cited by 73
Induction of Neuronal Differentiation of Murine N2a Cells by Two Polyphenols Present in the Mediterranean Diet Mimicking Neurotrophins Activities: Resveratrol and Apigenin
Namsi, A., Nury, T., Hamdouni, H., Yammine, A., Véjux, A., Fasseur, D., Latruffe, N., Masmoudi‐Kouki, O., & Lizard, G. (2018) · Diseases · doi:10.3390/diseases6030067 · Cited by 72
Environmental application of nanomaterials: A promise to sustainable future
Sohail, M. I., Waris, A. A., Ayub, M. A., Usman, M., Zia‐ur‐Rehman, M., Ṣābir, M., & Faiz, T. (2019) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2019.10.002 · Cited by 74
Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism
Tiwari, M. N., Agarwal, S., Bhatnagar, P., Singhal, N. K., Tiwari, S. K., Kumar, P., Chauhan, L. K. S., Patel, D. K., Chaturvedi, R. K., Singh, M. P., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.042 · Cited by 70
Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model
Meister, S., Zlatev, I., Stäb, J., Docter, D., Baches, S., Stauber, R. H., Deutsch, M., Schmidt, R., Ropele, S., Windisch, M., et al. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt225 · Cited by 73
Neurodegenerative diseases – Understanding their molecular bases and progress in the development of potential treatments
Rowińska‐Żyrek, M., Salerno, M., & Kozłowski, H. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.03.026 · Cited by 66
Nanoparticle mediated brain targeted delivery of gallic acid:in vivobehavioral and biochemical studies for improved antioxidant and antidepressant-like activity
Nagpal, K., Singh, S. K., & Mishra, D. N. (2012) · Drug Delivery · doi:10.3109/10717544.2012.738437 · Cited by 65
AmyloLipid Nanovesicles: A self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain delivery of curcumin
Sintov, A. C. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119725 · Cited by 67
The Tragedy of Alzheimer’s Disease: Towards Better Management via Resveratrol-Loaded Oral Bilosomes
Abbas, H., Gad, H. A., Khattab, M. A., & Mansour, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101635 · Cited by 62
Optimization of Curcumin-Loaded PEG-PLGA Nanoparticles by GSH Functionalization: Investigation of the Internalization Pathway in Neuronal Cells
Paka, G. D., & Ramassamy, C. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00738 · Cited by 62
Exploring the Influence of Carbon Nanoparticles on the Formation of β-Sheet-Rich Oligomers of IAPP22–28 Peptide by Molecular Dynamics Simulation
Guo, J., Li, J., Zhang, Y., Jin, X., Liu, H., & Yao, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065579 · Cited by 61
Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer’s disease
Sun, D., Zhang, W., Yu, Q., Chen, X., Xu, M., Zhou, Y., & Liu, J. (2017) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2017.06.083 · Cited by 61
110th Anniversary: Nanoparticle Mediated Drug Delivery for the Treatment of Alzheimer’s Disease: Crossing the Blood–Brain Barrier
Wechsler, M. E., Ramirez, J. E. V., & Peppas, N. A. (2019) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.9b02196 · Cited by 61
Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Teixeira, J., Silva, T., Andrade, P. B., & Borges, F. (2013) · Current Medicinal Chemistry · doi:10.2174/1871523011320240001 · Cited by 59
Effect of polymer architecture on curcumin encapsulation and release from PEGylated polymer nanoparticles: Toward a drug delivery nano-platform to the CNS
Rabanel, J., Faivre, J., Paka, G. D., Ramassamy, C., Hildgen, P., & Banquy, X. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.09.004 · Cited by 58
Methods for the In Vitro Characterization of Nanomedicines—Biological Component Interaction
Fornaguera, C., & Solans, C. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7010002 · Cited by 58
Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Micheli, M.-R., Bova, R., Magini, A., Polidoro, M., & Emiliani, C. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842241 · Cited by 58
The Potential Benefits of Nanotechnology in Treating Alzheimer’s Disease
Ling, T. S., Chandrasegaran, S., Low, Z. X., Suan, T. L., Elaine, E., Nathan, D. V., Chai, Y. H., Gunasekaran, B., & Salvamani, S. (2021) · BioMed Research International · doi:10.1155/2021/5550938 · Cited by 61
Anti-Aβ-MAb and dually decorated nanoliposomes: Effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells
Markoutsa, E., Παπαδιά, Κ., Clemente, C., Flores, O., & Antimisiaris, S. G. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.006 · Cited by 56
Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro of Nanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-Β Peptide
Sancini, G. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000171 · Cited by 53
Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy
Tosi, G., Pederzoli, F., Belletti, D., Vandelli, M. A., Forni, F., Duskey, J. T., & Ruozi, B. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.001 · Cited by 53
Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function
Sathya, S., Shanmuganathan, B., Saranya, S., Sethuraman, V., Kandasamy, R., & Devi, K. P. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1391822 · Cited by 51
Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer's disease
Liu, D., Li, W., Jiang, X., Bai, S., Liu, J., Liu, X., Shi, Y., Kuai, Z., Kong, W., Gao, R., et al. (2019) · Theranostics · doi:10.7150/thno.30649 · Cited by 49
Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Trompetero, A., Gordillo, A., del Pilar, M. C., Cristina, V., & Bustos, R. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170828133059 · Cited by 49
Quercetin-loaded selenium nanoparticles inhibit amyloid-β aggregation and exhibit antioxidant activity
Qi, Y., Yi, P., He, T., Song, X., Liu, Y., Li, Q., Zheng, J., Song, R., Liu, C., Zhang, Z., et al. (2020) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2020.125058 · Cited by 49
New Insights on the Biophysical Interaction of Resveratrol with Biomembrane Models: Relevance for Its Biological Effects
Neves, A. R., Nunes, C., & Reis, S. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b05419 · Cited by 48
Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future
Fazil, M., Shadab, Baboota, S., Sahni, J. K., & Ali, J. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.607499 · Cited by 47
Specific Frequency Electroacupuncture Stimulation Transiently Enhances the Permeability of the Blood-Brain Barrier and Induces Tight Junction Changes
Zhang, S., Gong, P., Zhang, J., Mao, X., Zhao, Y., Wang, H., Gan, L., & Lin, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.582324 · Cited by 47
Neuroprotective Effects ofCastanea sativaMill. Bark Extract in Human Neuroblastoma Cells Subjected to Oxidative Stress
Brizi, C., Santulli, C., Micucci, M., Budriesi, R., Chiarini, A., Aldinucci, C., & Frosini, M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25302 · Cited by 48
Impact of nanoparticles on amyloid β-induced Alzheimer’s disease, tuberculosis, leprosy and cancer: a systematic review
Chakraborty, A., Mohapatra, S. S., Barik, S., Roy, I., Gupta, B., & Biswas, A. (2023) · Bioscience Reports · doi:10.1042/bsr20220324 · Cited by 47
Negatively charged hydrophobic nanoparticles inhibit amyloid β-protein fibrillation: The presence of an optimal charge density
Liu, H., Xie, B., Dong, X., Zhang, L., Wang, Y., Liu, F., & Sun, Y. P. (2016) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2016.04.003 · Cited by 44
Nanoneuromedicine for management of neurodegenerative disorder
Dwivedi, N., Shah, J., Mishra, V. K., Tambuwala, M. M., & Kesharwani, P. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.021 · Cited by 44
Synergistic effects of negatively charged hydrophobic nanoparticles and (−)-epigallocatechin-3-gallate on inhibiting amyloid β-protein aggregation
Liu, H., Yu, L., Dong, X., & Sun, Y. P. (2016) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2016.12.038 · Cited by 43
Preparation and characterization of curcumin‐loaded polymeric nanomicelles to interference with amyloidogenesis through glycation method
Mirzaie, Z., Ansari, M., Kordestani, S. S., Habibi-Rezaei, M., & Mozafari, M. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1751 · Cited by 44
Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Rocha, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990613 · Cited by 42
Development and evaluation of protamine-coated PLGA nanoparticles for nose-to-brain delivery of tacrine: In-vitro and in-vivo assessment
Shamarekh, K. S., Gad, H. A., Soliman, M. E., & Sammour, O. A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101724 · Cited by 42
Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils
Margel, S., Skaat, H., Corem‐Salkmon, E., Grinberg, I., Last, D., Goez, D., & Mardor, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s52833 · Cited by 43
Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Altinoglu, G., & Adalı, T. (2019) · Current Drug Targets · doi:10.2174/1389450120666191118123151 · Cited by 41
Nano‐delivery systems as a promising therapeutic potential for epilepsy: Current status and future perspectives
Movahedpour, A., Taghvaeefar, R., Asadi‐Pooya, A. A., Karami, Y., Tavasolian, R., Khatami, S. H., Fard, E. S., Taghvimi, S., Karami, N., Jaberi, K. R., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14355 · Cited by 40
Co-encapsulation ofNigella sativaoil and plasmid DNA for enhanced gene therapy of Alzheimer’s disease
Doolaanea, A. A., Mansor, N. I., Nor, N. H. M., & Mohamed, F. (2016) · Journal of Microencapsulation · doi:10.3109/02652048.2015.1134689 · Cited by 39
Gallic acid‐gold nanoparticles enhance radiation‐induced cell death of human glioma U251 cells
Zhou, J., Li, M., Wang, H., Yang, Z., Zhou, S., Ma, J., Meng, E., Zhang, H., Liang, W., Hu, W., et al. (2020) · IUBMB Life · doi:10.1002/iub.2436 · Cited by 39
Polymeric Nanocarriers for Controlled and Enhanced Delivery of Therapeutic Agents to the CNS
Gagliardi, M., Bardi, G., & Bifone, A. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.55 · Cited by 36
Delivery systems for theranostics in neurodegenerative diseases
Li, Y., Liu, R., Ji, W., Li, Y., Liu, L., & Zhang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2067-z · Cited by 35
Improving drug delivery technology for treating neurodegenerative diseases
Choonara, Y. E., Kumar, P., Modi, G., & Pillay, V. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1162152 · Cited by 34

Authors: Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C.
Affiliations: Institut National de la Recherche Scientifique (CA)
Jamia Hamdard (IN)
Corresponding author: Ramassamy, Charles
ORCID: Ali, Javed
Baboota, Sanjula
Ramassamy, Charles
Venue: Journal of Controlled Release
Publisher: Elsevier BV
Published: 2011-06
Volume: 152
Issue: 2
Pages: 208-231
ISSN: 0168-3659 (ISSN-L)
DOI: 10.1016/j.jconrel.2010.11.033
OpenAlex: W2040364087
Cited by: 219
References: 352
Citations by year: 2026: 4 · 2025: 10 · 2024: 11 · 2023: 14 · 2022: 17 · 2021: 14 · 2020: 16 · 2019: 21 · 2018: 18 · 2017: 14 · 2016: 17 · 2015: 16 · 2014: 13 · 2013: 15 · 2012: 13
FWCI: 0.54
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Controlled Release (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
EspaceINRS (National Institute for Scientific Research (Canada)) (submittedVersion)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords: Alzheimer's disease, nanoparticles, nanocarriers, blood-brain barrier, targeted drug delivery, brain drug delivery, drug encapsulation, nanomedicine, route of administration, neurodegenerative diseases
MeSH terms: Alzheimer Disease, Amyloid, Animals, Blood-Brain Barrier, Chelating Agents, Cholinesterase Inhibitors, Flavonoids, Hormones, Humans, Phenols, Vasoactive Intestinal Peptide, Drug Delivery Systems, Nanoparticles, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neurotherapeutic applications of nanoparticles in Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks